Evidence map›Paper›PMID 28232864›Full record

ArticleF1000Research2016

The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome.

Peter Humaidan, Carlo Alviggi, Robert Fischer, Sandro C Esteves

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 142 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04719000 phase4recruitingnot on this mapstarted 2021, after this paper: background citation

PErsonalized Addition of Recombinant LH in Suboptimal Responders >35 Years Old (POSEIDON Group 2): A Randomized Controlled Trial

TypeinterventionalSponsorFundación Santiago Dexeus FontRan2021 to 2027Enrolled120ConditionsInfertilityArmsrhFSH+rhLH, rhFSH
NCT05281341 phase4completednot on this mapstarted 2020, after this paper: background citation

Effect of Growth Hormone Administration With Controlled Ovarian Stimulation in Expected Poor Responders POSEIDON Group 3 and 4 Undergoing ICSI Using Antagonist Protocol

TypeinterventionalSponsorAlexandria UniversityRan2020 to 2022Enrolled160ConditionsFemale InfertilityArmsGrowth Hormone
3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Growth hormone for in vitro fertilisation (IVF).The Cochrane database of systematic reviews · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Ovarian reserve and endothelial health in healthy reproductive-age women.The Journal of clinical endocrinology and metabolism · 2026
    Article
  18. Article
  19. Article
  20. Article

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peter HumaidanFertility Clinic, Skive Regional Hospital, Skive, Denmark; Faculty of Health, Aarhus University, Skive, Denmark.
Carlo AlviggiDepartment of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Naples, Italy.
Robert FischerFertility Center Hamburg, Hamburg, Germany.
Sandro C EstevesANDROFERT, Andrology & Human Reproduction Clinic, Campinas, Brazil.ORCID 0000-0002-1313-9680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In reproductive medicine little progress has been achieved regarding the clinical management of patients with a reduced ovarian reserve or poor ovarian response (POR) to stimulation with exogenous gonadotropins -a frustrating experience for clinicians as well as patients. Despite the efforts to optimize the definition of this subgroup of patients, the existing POR criteria unfortunately comprise a heterogeneous population and, importantly, do not offer any recommendations for clinical handling. Recently, the POSEIDON group (

Indexed as

Assisted Reproductive TechnologyDiagnosisEmbryo aneuploidyGonadotropinsGroup POSEIDONOvarian stimulationPoor ovarian responsePrognosis.

Identifiers

PMID28232864
PMCPMC5302217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.